Symbols

IBRX

ImmunityBio·NASDAQ

--(--)

IBRX fundamentals

IBRX Q4 2025 Earnings

ImmunityBio (IBRX) released its earnings on Feb 23, 2026: revenue was 38.28M (YoY +406.95%), missed estimates; EPS was -0.06 (YoY +33.33%), beat estimates.

Revenue / YoY

38.28M

+406.95%

EPS / YoY

-0.06

+33.33%

Report date

Feb 23, 2026

IBRX Earnings Call Summary for Q4,2025

700% Revenue Growth: ANKTIVA net product revenue reached $113 million in 2025, up from $14.1 million in 2024.
Global Expansion: 33-country footprint, including EU and Saudi Arabia approvals for bladder and lung cancer.
Innovative Platform: BioShield combines ANKTIVA with checkpoint inhibitors, cell therapies, and vaccines to treat cancer and lymphopenia.
AI-Driven Manufacturing: NantLeonardo platform scales cell therapy production at low cost.
Lung Cancer Breakthrough: Saudi Arabia first to approve ANKTIVA + checkpoint inhibitors for metastatic NSCLC.

Earnings

EPS

Revenue

Revenue & Expenses

IBRX has released its 2025 Q4 earnings report, with revenue of 38.28M, reflecting a YoY change of 406.95%, and net profit of -61.96M, showing a YoY change of -4.70%. The Sankey diagram below clearly presents IBRX's revenue sources and cost distribution.

Key Indicators

ImmunityBio (IBRX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

ImmunityBio (IBRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

ImmunityBio (IBRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

ImmunityBio (IBRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown